A First-in-Human Phase I, Open Label, Multiple Dose, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of Anti-BAFFR mAb, ESG206 in Subjects With B-cell Lymphoid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ESG 206 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Adverse reactions; First in man
Sponsors Shanghai Escugen Biotechnology

Most Recent Events

19 Jul 2024 Planned End Date changed from 1 May 2025 to 1 Dec 2026.
19 Jul 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Aug 2026.
19 Jul 2024 Planned initiation date changed from 1 Jun 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight